MOMamadou Ouattara

Mamadou Ouattara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mamadou Ouattara has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Prevalence of Toxoplasmosis Antibodies Among Pregnant Women Attending Antenatal Care Services in Urban and Rural Health Facilities in Three Regions of Burkina Faso: A Cross‐Sectional Study

    by Achille Sindimbasba Nikièma, Armel Moumouni Sanou, Mamadou Ouattara, Barnabé Relwendé Yaméogo, Ad Bafa Ibrahim Ouattara, Mariam Seynou, Djara Konaté, Nina Geneviève Mathuola Ouattara, Dieudonné Ilboudo, Ina Marie Angèle Traoré, et al.

    Background and Aims: Congenital toxoplasmosis can cause severe diseases to the fetus and newborns or abortion, and is associated with significant morbidity and mortality. In Burkina Faso, while seroprevalence data for toxoplasmosis are available for urban areas, such data are scarce for rural areas. This study aims to determine the seroprevalence of toxoplasmosis in pregnant women attending antenatal services in primary health facilities in rural and urban areas. Methods: A cross‐sectional study was conducted between July 2022 and June 2023 in health facilities located in the Cascades ( n = 2), Hauts‐Bassins ( n = 2), and Sud‐Ouest ( n = 2) regions. All pregnant women attending the health facilities for antenatal care who consented to participate in the study were enrolled. Venous blood samples were collected from each pregnant woman, and serum was analyzed for IgG and IgM antibodies using a rapid diagnostic test. Seroprevalences of IgM and IgG were determined. The association between seroprevalence and socio‐demographic characteristics was assessed by bivariate and multivariate analyses. Results: A total of 2509 pregnant women were enrolled and screened. Their mean age was 25.71 years, and the overall seroprevalence (IgM‐positive and or IgG‐positive) was 29.33% (736) (95% CI: 27.56–31.16). Of the 736 women tested positive for both antibodies, 27 were seropositive for IgM antibody; 703 for IgG antibody and 6 for both antibody (Ig M; Ig G). No statistically differences were observed in the seroprevalence according to age, place of residence (rural, urban), and educational level of the participant ( p = 0.002). Conclusion: The results of our study indicate a high seroprevalence of toxoplasmosis among pregnant women, with no statistically difference between rural and urban areas. Some women acquired the infection during pregnancy, underscoring the risk of congenital toxoplasmosis. Health authorities should integrate toxoplasmosis diagnosis into a free antenatal screening program to facilitate the detection of toxoplasmosis during pregnancy and prevent congenital toxoplasmosis.

  • Open Access

    Exploring Heterogeneity in Treatment Effects: The Impact and Interaction of Asset-Based Wealth and Mass Azithromycin Distribution on Child Mortality

    by Elisabeth A. Gebreegziabher, Ali Sie, Mamadou Ouattara, Mamadou Bountogo, Boubacar Coulibaly, Valentin Boudo, Thierry Ouedraogo, Elodie Lebas, Huiyu Hu, Pearl Anne Ante-Testard, et al.

    Objective To examine how child mortality among children aged 1–59 months varies by asset-based wealth status in rural Burkina Faso and to assess the interaction between mass azithromycin distribution and wealth status on child mortality at both the household and community levels. Methods We used data from a cluster-randomized trial and a population census data on household characteristics and assets. A wealth index score for each household, used to classify the population by wealth was generated using principal component analysis. We used the Relative Index of Inequality (RII), the Slope Index of Inequality (SII), and the concentration index to assess wealth-related inequalities in mortality, and the Gini Index to assess variability in child mortality across households and communities. Poisson regression models were used with person-time at risk included as an offset and robust standard error to estimate changes in mortality rates by wealth and treatment arm. We assessed interaction on both the multiplicative and additive scales. Results Mortality declined with increasing wealth at both household and community levels, with a significant gradient at the community level (RII = 1.17, 95% CI: 1.05–1.29; SII = 2.3 per 1,000 person-years, 95% CI: 0.2–4.4), reflecting higher mortality among the poorest. The effect of AZ did not vary significantly by wealth index, and the change in mortality rates across wealth levels was similar between the two treatment arms. There was no statistically significant interaction between AZ and asset-based wealth on either a multiplicative or additive scale at the household or cluster level. Conclusion Our findings show a wealth gradient in child mortality, with households and communities in the poorest quintiles experiencing the highest mortality rates. These disparities were consistent across both AZ-treated and placebo groups, suggesting that AZ’s role in health disparities may primarily address gaps in treatment access rather than broader wealth-related disparities. AZ appears to offer similar benefits across economically diverse communities, with no evidence suggesting enhanced benefits for disadvantaged communities or for prioritizing treatment based on wealth status. Further work is needed to address the wealth-related disparities in child mortality in these communities. Trial Registration ClinicalTrials.gov Identifier: NCT03676764

  • Open Access

    Mass azithromycin for prevention of child mortality among children with acute malnutrition: A subgroup analysis of a cluster randomized controlled trial

    by Ali Sié, Mamadou Ouattara, Mamadou Bountogo, Valentin Boudo, Thierry Ouedraogo, Clarisse Dah, Guillaume Compaoré, Elodie Lebas, Huiyu Hu, Travis C. Porco, et al.

    Children with acute malnutrition are at high risk of morality. Mass azithromycin distribution reduces all-cause mortality among children aged 1–59 months, and effects may be greater in underweight infants. Here, we evaluate the efficacy of azithromycin for reducing all-cause mortality in children aged 6–59 months with acute malnutrition (mid-upper arm circumference, MUAC, < 12.5 cm). Communities in Nouna District, Burkina Faso were 1:1 randomized to biannual mass distribution of single dose azithromycin or placebo to all children aged 1–59 months. Mortality was assessed during each census and treatment round. MUAC measurements were collected for all children. We evaluated the effect of azithromycin on mortality in subgroups of children aged 6–59 months defined by acute malnutrition (MUAC < 12.5 cm versus MUAC ≥ 12.5 cm). In children with MUAC < 12.5 cm, mortality rates were 51% lower among those living in azithromycin communities compared to placebo (incidence rate ratio 0.49, 95% confidence interval, CI, 0.25 to 0.99; incidence rate difference -18.1 deaths per 1,000 person-years, 95% CI -37.0 to -0.01), which was greater than the reduction in mortality among children with MUAC ≥ 12.5 cm (P-value for interaction on the relative scale = 0.09; P-value for interaction of the additive scale = 0.03). Children with acute malnutrition may benefit from single dose azithromycin above and beyond those without acute malnutrition. Trial registration: ClinicalTrials.gov NCT03676764; https://clinicaltrials.gov/study/NCT03676764


  • Open Access

    Single-dose azithromycin for infant growth in Burkina Faso: Prespecified secondary anthropometric outcomes from a randomized controlled trial

    by Ali Sié, Mamadou Ouattara, Mamadou Bountogo, Clarisse Dah, Thierry Ouedraogo, Valentin Boudo, Elodie Lebas, Huiyu Hu, Benjamin F Arnold, Kieran S O'Brien, et al.

    Background: Antibiotic use during early infancy has been linked to childhood obesity in high-income countries. We evaluated whether a single oral dose of azithromycin administered during infant-well visits led to changes in infant growth outcomes at 6 months of age in a setting with a high prevalence of undernutrition in rural Burkina Faso. Methods and findings: Infants were enrolled from September 25, 2019, until October 22, 2022, in a randomized controlled trial designed to evaluate the efficacy of a single oral dose of azithromycin (20 mg/kg) compared to placebo when administered during well-child visits for prevention of infant mortality. The trial found no evidence of a difference in the primary endpoint. This paper presents prespecified secondary anthropometric endpoints including weight gain (g/day), height change (mm/day), weight-for-age Z-score (WAZ), weight-for-length Z-score (WLZ), length-for-age Z-score (LAZ), and mid-upper arm circumference (MUAC). Infants were eligible for the trial if they were between 5 and 12 weeks of age, able to orally feed, and their families were planning to remain in the study area for the duration of the study. Anthropometric measurements were collected at enrollment (5 to 12 weeks of age) and 6 months of age. Among 32,877 infants enrolled in the trial, 27,298 (83%) were followed and had valid anthropometric measurements at 6 months of age. We found no evidence of a difference in weight gain (mean difference 0.03 g/day, 95% confidence interval (CI) −0.12 to 0.18), height change (mean difference 0.004 mm/day, 95% CI −0.05 to 0.06), WAZ (mean difference −0.004 SD, 95% CI −0.03 to 0.02), WLZ (mean difference 0.001 SD, 95% CI −0.03 to 0.03), LAZ (mean difference −0.005 SD, 95% CI −0.03 to 0.02), or MUAC (mean difference 0.01 cm, 95% CI −0.01 to 0.04). The primary limitation of the trial was that measurements were only collected at enrollment and 6 months of age, precluding assessment of shorter-term or long-term changes in growth. Conclusions: Single-dose azithromycin does not appear to affect weight and height outcomes when administered during early infancy. Trial registration: ClinicalTrials.gov NCT03676764


  • Open Access

    Profil des utilisatrices et facteurs associés à la satisfaction des clientes de la qualité des soins après avortement au Burkina Faso: étude transversale menée dans six régions

    by Mamadou Ouattara, Ali Sié, Mariam Seynou, Moubassira Kagoné, Mamadou Bountogo, Idrissa Kouanda, Ramatou Ouédraogo, Martin Bangha, Kenneth Juma, Sherine Athero

    RésuméMalgré la dépénalisation de l'avortement et la gratuité des soins après avortement (SAA), les femmes Burkinabè vivent des relations difficiles avec les soignants. Cette étude vise à déterminer le profil des femmes recevant des SAA, leur perception de la qualité des SAA et ses déterminants dans des structures sanitaires publiques et confessionnelles du pays. Une enquête quantitative a été menée auprès de 2174 femmes vues pour des SAA et recrutées de façon exhaustive de 2018 à 2020. Un questionnaire structuré a été administré à la sortie des soins. Une analyse uni-, bi- et multivariée a été faite. La majorité des clientes de SAA vivait en milieu rural (55%), avait 25 ans et plus (60%), vivait en couple (87%) et était sans-emploi (59%). La grossesse était non désirée chez 17% des femmes et 4% d'entre elles souhaitaient avorter. La satisfaction globale de la qualité des SAA était de 84%. Dans l'analyse multivariée, ses déterminants étaient la résidence en milieu rural (OR = 1.80 [1.38; 2.34]), un niveau scolaire primaire (OR = 1.48 [1.06; 2.07]) ou secondaire (OR = 1.95 [1.38; 2.74]), et avoir eu au moins un enfant (OR = 1.43 [1.02; 2.00]). Les facteurs associés à une faible satisfaction des SAA étaient une grossesse non désirée (OR = 0.64 [0.46; 0.89]) ou avoir souhaité avorter (OR = 0.09 [0.05; 0.16]). Le niveau de satisfaction globale est acceptable mais faible chez les clientes ayant souhaité avorter. Il est fondamental d'organiser un programme de formation des professionnels des SAA sur la communication, la relation interpersonnelle et l'empathie pendant les soins de santé.


  • Open Access

    Residual risk of hepatitis B virus transmission through blood donations in Burkina Faso screened with rapid diagnostic tests

    by Armel M. Sanou, Achille S. Nikièma, Seimbou Zalla, Mamadou Ouattara, Nina Pascaline S. Dakouo, Alice Kiba‐Koumare, Mariam Seynou, Delphine Napon‐Zongo, Roger Sombié

    Background and Aims: hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) represent the major transfusion–transmissible pathogens worldwide. The risk of transmission is relatively high in African countries, mainly due to unreliable screening methods of blood donations. In Burkina Faso, predonation screening using rapid diagnostic tests (RDTs) is widespread, raising the major question of the transfusion safety in the country. The objective of this study was to assess the risk of transmission of HBV, HCV, and HIV through blood transfusion in the context of the use of RDTs for screening of the blood donations.Methods: In this cross‐sectional study, a total of 417 serum samples obtained from blood donors tested negative for HBsAg, anti‐HCV, and anti‐HIV using RDTs were retested for the same markers using chemiluminescent immunologic assays. Total antibodies to HBV core (anti‐HBc) were tested on randomly selected samples. HBV‐DNA and HCV‐RNA viral loads (VLs) were quantified on HBsAg and anti‐HCV positive samples, respectively. To assess possible occult hepatitis B infection (OBI), HBV‐DNA‐VL was quantified on 313 randomly selected HBsAg‐negative samples.Results: HBsAg and anti‐HCV were found respectively in 6 (6/417; 1.4%) and 11 (11/417; 2.6%) samples. No samples were reactive for anti‐HIV. Total anti‐HBc were detected in 217 out of the 319 randomly selected samples (217/319; 68.02%). HBV‐DNA was detected in four (4/313; 1.27%) samples, including two (2/6; 33.33%) of the six HBsAg positive samples and two (2/313; 0.6%) of the HBsAg‐negative samples, suggesting two cases of occult HBV infection. All anti‐HCV antibody‐positive samples were HCV‐RNA negative.Conclusion: This study shows that RDTs are not sufficiently sensitive for the screening of blood donations. Our results highlight the urgent need to think about the extension of sensitive immunological tests in all blood transfusion centers and also the implementation of nucleic acid amplification techniques.


  • Open Access

    Cause-specific childhood mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites

    by P. Kim Streatfield, Wasif A. Khan, Abbas Bhuiya, Syed M.A. Hanifi, Nurul Alam, Mamadou Ouattara, Aboubakary Sanou, Ali Sié, Bruno Lankoandé, Abdramane B. Soura, et al.

    BackgroundChildhood mortality, particularly in the first 5 years of life, is a major global concern and the target of Millennium Development Goal 4. Although the majority of childhood deaths occur in Africa and Asia, these are also the regions where such deaths are least likely to be registered. The INDEPTH Network works to alleviate this problem by collating detailed individual data from defined Health and Demographic Surveillance sites. By registering deaths and carrying out verbal autopsies to determine cause of death across many such sites, using standardised methods, the Network seeks to generate population-based mortality statistics that are not otherwise available.ObjectiveTo present a description of cause-specific mortality rates and fractions over the first 15 years of life as documented by INDEPTH Network sites in sub-Saharan Africa and south-east Asia.DesignAll childhood deaths at INDEPTH sites are routinely registered and followed up with verbal autopsy (VA) interviews. For this study, VA arch...


  • Open Access

    Survie et croissance des juvéniles hybrides issus du croisement intergénérique Oreochromis niloticus (linnaeus, 1758) et Sarotherodon melanotheron (rüppel, 1852) en milieu lagunaire

    by Yn Amon, K Yao, Bc Atse, M Ouattara

    Survie et croissance des juvéniles hybrides issus du croisement intergénérique Oreochromis niloticus (linnaeus, 1758) et Sarotherodon melanotheron (rüppel, 1852) en milieu lagunaire